Brooks Laboratories Ltd's Q4FY25 Quarter Results
- 29 May 2025
Result Summary
- Brooks Laboratories Ltd reported a 52.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 45.5%.
- Its expenses for the quarter were down by 52.2% QoQ and up 35.4% YoY.
- The net profit increased 110.3% QoQ and increased 123.5% YoY.
- The earnings per share (EPS) of Brooks Laboratories Ltd declined at 3.8 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 18.38 | 38.55 | 12.63 | -52.3% | 45.5% |
Total Expenses | 18.07 | 37.82 | 13.35 | -52.2% | 35.4% |
Profit Before Tax | 0.30 | 0.72 | -0.72 | -58.3% | -141.7% |
Tax | 0.00 | 0.03 | 0.00 | -100.0% | - |
Profit After Tax | -9.61 | -4.57 | -4.30 | 110.3% | 123.5% |
Earnings Per Share | -3.80 | -1.80 | -1.70 | 111.1% | 123.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Brooks Laboratories Ltd is a pharmaceutical company engaged in the manufacturing of pharmaceutical formulations. The company's main products include a range of therapeutic injectables, oral formulations, and other pharmaceutical products. Brooks Laboratories operates in the healthcare and pharmaceutical industry, which is characterized by stringent regulations, high research and development costs, and competitive markets. As of the latest data, there are no specific major developments reported for Brooks Laboratories Ltd that could be highlighted in this report. The company’s operations are likely influenced by factors typical to the pharmaceutical sector, such as regulatory approvals, market demand for generic versus patented drugs, and healthcare policies.
Revenue
For the fourth quarter of fiscal year 2025 (Q4FY25), Brooks Laboratories reported a total income of ₹18.38 crore. This reflects a decline of 52.3% on a quarter-over-quarter (QoQ) basis from ₹38.55 crore reported in the third quarter of fiscal year 2025 (Q3FY25). However, on a year-over-year (YoY) basis, the total income increased by 45.5% compared to ₹12.63 crore in the fourth quarter of fiscal year 2024 (Q4FY24). The decrease in revenue QoQ might suggest seasonal variations or market conditions affecting the sales during the quarter, while the YoY growth indicates a substantial increase in revenue compared to the previous year.
Profitability
Brooks Laboratories recorded a profit before tax (PBT) of ₹0.30 crore in Q4FY25, showing a decrease of 58.3% compared to the ₹0.72 crore reported in Q3FY25. However, this represents an improvement from a loss before tax of ₹-0.72 crore in Q4FY24. The company did not incur any tax expense in Q4FY25, similar to Q4FY24, but saw a decrease from ₹0.03 crore in Q3FY25. The profit after tax (PAT) for Q4FY25 was negative at ₹-9.61 crore, which increased by 110.3% QoQ from ₹-4.57 crore in Q3FY25, and by 123.5% YoY from ₹-4.30 crore in Q4FY24. Earnings per share (EPS) followed a similar pattern, recorded at ₹-3.80 in Q4FY25, reflecting a QoQ increase of 111.1% and a YoY increase of 123.5%.
Operating Metrics
The total expenses for Q4FY25 were ₹18.07 crore, representing a 52.2% decrease from ₹37.82 crore in Q3FY25, while showing a 35.4% increase from ₹13.35 crore in Q4FY24. The significant reduction in expenses QoQ aligns closely with the decrease in total income, suggesting parallel trends in cost management or reductions in operational activity during the period. The YoY increase in expenses, albeit moderate compared to income growth, indicates changes in operational scale or input costs relative to the prior year. The financial data does not provide specific operational metrics like P/E ratio, debt-to-equity ratio, or current ratio, thus these cannot be calculated from the provided data.